BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Centre de Recherches en Cancérologie de Toulouse - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Centre de Recherches en Cancérologie de Toulouse
X-ORIGINAL-URL:https://www.crct-inserm.fr
X-WR-CALDESC:Évènements pour Centre de Recherches en Cancérologie de Toulouse
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260901T133000
DTEND;TZID=Europe/Paris:20260901T143000
DTSTAMP:20260810T183955
CREATED:20260727T142958Z
LAST-MODIFIED:20260730T115924Z
UID:64383-1788269400-1788273000@www.crct-inserm.fr
SUMMARY:Conférence Keisuke Ito - Mitochondrial metabolism shaping hematopoietic stem cell fate and its therapeutic targeting in hematological disorders
DESCRIPTION:Biosketch/Roles\nProfessor of Cell Biology\, Medicine\, and Oncology\nDirector of Scientific Resources of the Stem Cell Institute \nSeminar Abstract\nThe Ito lab aims to illuminate the pathways that govern stem cell self-renewal and differentiation. They have developed single‑cell approaches that reveal mitophagy driven by fatty acid (FA) metabolism as a key driver of hematopoietic stem cell (HSC) self‑renewal (Science 2016; Exp Hematology 2018; Stem Cell Research 2019). In situ analyses with Dr. Lucas identified cells and structures enabling both normal and stress hematopoiesis (Nature\, 2024). They explored how mitochondrial FA metabolism shapes HSC fate and roles of extracellular vesicles in maintaining HSC properties (Cell Stem Cell\, 2024). They also studied mitochondrial involvement in AML\, retinoic acid signaling\, and clonal hematopoiesis with Drs. Cabezas‑Wallscheid (Cell Stem Cell 2022) and de Thé (Cancer Discov 2021)\, and more recently with Drs. Trowbridge (Nat Commun 2025) and van Gastel (Cancer Metab 2025). Furthermore\, their research focuses include mitochondria-associated membranes (MAMs) as dynamic ER-mitochondria communication hubs (e.g.\, Science 2010; Cell Death Differ 2023)\, and their translational work on STAT3 degradation for leukemia therapy was just published (Leukemia\, Feb 2026). They identified Nucleophosmin 1 (NPM1) as a regulator of HSC aging and inflammation in MDS pathogenesis (EMBO Reports 2022). Finally\, their collaborative work with Dr. Meelad Dawlaty’s lab revealed non‑catalytic Tet2 requirements in hematopoiesis (Cell Reports 2019; Science Advances 2022; Exp Hematology 2023; HemaSphere 2025).
URL:https://www.crct-inserm.fr/evenement/conference-keisuke-ito-mitochondrial-metabolism-shaping-hematopoietic-stem-cell-fate-and-its-therapeutic-targeting-in-hematological-disorders/
LOCATION:Amphithéâtre IUCT-Oncopole
CATEGORIES:Animation scientifique
ATTACH;FMTTYPE=image/png:https://www.crct-inserm.fr/wp-content/uploads/2026/07/conference-Keisuko-Ito-0109-carre.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261030T110000
DTEND;TZID=Europe/Paris:20261030T120000
DTSTAMP:20260810T183955
CREATED:20260731T105041Z
LAST-MODIFIED:20260731T105219Z
UID:64401-1793358000-1793361600@www.crct-inserm.fr
SUMMARY:Conférence Anna Labernadie - Micro Immune Response On-chip (MIRO) : a model of tumour-stroma interface for immunotherapy testing
DESCRIPTION:Micro Immune Response On-chip (MIRO): a model of tumour-stroma interface for immunotherapy testing \nDr Anna Labernadie – Group Leader Cell Behaviour and Tissue Bioengineering Team\,  Príncipe Felipe Research Center (CIPF) Valencia Spain \nConference sponsored by SFR B2S on Friday October 30th 2026 \nAbstract:\nImmunotherapies represent a major advance in cancer treatment\, yet only 20–40% of patients derive benefit. To improve treatment prediction\, models that accurately reflect tumour architecture and the interplay between cancer cells and the microenvironment are essential. In this study\, we introduce Micro Immune Response On‑chip (MIRO)\, an ex vivo platform that generates 3D barriers built by cancer‑associated fibroblasts (CAFs) and their secreted extracellular matrix\, which enclose cancer cell clusters. We applied MIRO to study resistance to antibody‑dependent cellular cytotoxicity (ADCC) under targeted therapies. Our results indicate that stromal barriers are associated with immune exclusion and reduced ADCC efficacy. We further show that IL2 stimulation enhances immune cell velocity\, counteracting stromal immunosuppression. This restoration of immune activity demonstrates the ability of IL2 to overcome stroma‑mediated resistance. Overall\, MIRO emerges as a translational platform for drug testing and for evaluating novel immunotherapeutic strategies. \nBio:\nDr. Anna Labernadie heads the Cell Behaviour and Tissue Bioengineering group at the Príncipe Felipe Research Center (CIPF) in Valencia. Her work centers on mechano-oncology\, with a particular focus on how mechanosensing shapes tumor dissemination and modulates immune responses in cancer. To investigate these processes\, her team integrates biophysical methods\, cellular co-culture systems\, and organ-on-chip technologies\, aiming to replicate the physical constraints\, cell–cell interactions\, and spatial organization characteristic of tissues and tumors. \nShe earned her PhD in Cell Biology from the University of Toulouse in 2012\, and then conducted postdoctoral research in the laboratory of Xavier Trepat at IBEC (Barcelona)\, where she studied the physical interplay between tumor cells and stromal fibroblasts during cancer progression. In 2022\, she was awarded a Ramón y Cajal Fellowship\, enabling her to establish her independent research group at the CIPF. \nHer team actively collaborates with academic\, clinical\, and industrial partners to develop advanced on-chip platforms for investigating cell mechanics across a wide range of physiological and disease contexts. \nWeb: https://www.cipf.es/ \nPublications:\nMicro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing. Perucca A\, Llonín AG\, Benach OM\, et al.\, Nature Communications 2025 Feb\,  DOI:  10.1038/s41467-025-56275-1.\nMembrane to cortex attachment determines different mechanical phenotypes in LGR5+ and LGR5- colorectal cancer cells. Conti S\, et al.\, Nature Communications 2024 Apr\,  DOI:  10.1038/s41467-024-47227-2.\nA mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. Labernadie A\, et al.\, Nature Cell Biology 2017 Mar\,  DOI:  10.1038/ncb3478.\nProtrusion force microscopy reveals oscillatory force generation and mechanosensing activity of human macrophage podosomes. Labernadie\, A.\, et al.\, Nature Communications  2014\, DOI: 10.1038/ncomms6343.
URL:https://www.crct-inserm.fr/evenement/conference-anna-labernadie-micro-immune-response-on-chip-miro-a-model-of-tumour-stroma-interface-for-immunotherapy-testing/
LOCATION:Salle Cazaux + Visio Teams
CATEGORIES:Animation scientifique
ATTACH;FMTTYPE=image/png:https://www.crct-inserm.fr/wp-content/uploads/2026/07/conference-Anna-Labernadie-301026-carre.png
END:VEVENT
END:VCALENDAR